tacrolimus + ARM + mycophenolate mofetil + cyclophosphamide

This is a multi-drug combination therapy consisting of tacrolimus, ARM (unknown or unspecified agent), mycophenolate mofetil (MMF), and cyclophosphamide. Such combinations are used as immunosuppressive regimens, particularly in the management of severe autoimmune diseases like lupus nephritis and in post-transplant settings to prevent organ rejection. - **Tacrolimus** is a calcineurin inhibitor that suppresses T-cell activation by inhibiting interleukin-2 transcription[6][8][10]. - **Mycophenolate mofetil** inhibits inosine monophosphate dehydrogenase, blocking purine synthesis required for lymphocyte proliferation. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA, leading to suppression of rapidly dividing immune cells[1][3][4][5]. The mechanism and role of "ARM" are unclear from available sources; it may refer to an investigational or regionally specific immunosuppressant or could be a placeholder for "arm" in clinical trial design rather than an actual drug. Multi-targeted regimens combining these agents aim to maximize immunosuppression while minimizing toxicity by using lower doses of each component. This approach has been studied primarily in refractory lupus nephritis and transplant medicine[1][3][4][5].

Other names

tacrolimus + ARM + MMF + cyclophosphamide